490 related articles for article (PubMed ID: 35426599)
21. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
22. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
[TBL] [Abstract][Full Text] [Related]
23. Comparison of
Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
25. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
[TBL] [Abstract][Full Text] [Related]
26. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
27.
Li TC; Wang Y; Xiao CT; Li MZ; Liu XP; Huang WT; Li LY; Li K; Di JM; Wen XQ; Gao X
Asian J Androl; 2022; 24(1):97-101. PubMed ID: 34213490
[TBL] [Abstract][Full Text] [Related]
28.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.
Maurer T; Weirich G; Schottelius M; Weineisen M; Frisch B; Okur A; Kübler H; Thalgott M; Navab N; Schwaiger M; Wester HJ; Gschwend JE; Eiber M
Eur Urol; 2015 Sep; 68(3):530-4. PubMed ID: 25957851
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
[TBL] [Abstract][Full Text] [Related]
31. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH; Schilham M; Hermsen R; de Baaij JMS; Vrijhof HJEJ; Hoekstra RJ; Sedelaar JPM; Küsters-Vandevelde HVN; Gotthardt M; Wijers CHW; van Basten JP; Somford DM
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):65-70. PubMed ID: 34471231
[TBL] [Abstract][Full Text] [Related]
32.
Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
[TBL] [Abstract][Full Text] [Related]
33. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of
Koehler D; Sauer M; Klutmann S; Apostolova I; Lehnert W; Budäus L; Knipper S; Maurer T
J Nucl Med; 2023 Jan; 64(1):59-62. PubMed ID: 35835582
[TBL] [Abstract][Full Text] [Related]
35. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Tilki D; Mansholt J; Berliner C; Bernreuther C; Steuber T; Maurer T; Graefen M
Eur Urol Focus; 2019 Jan; 5(1):50-53. PubMed ID: 30292421
[TBL] [Abstract][Full Text] [Related]
36. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
[TBL] [Abstract][Full Text] [Related]
37. Delayed Imaging Improves Lesion Detectability in [
Berliner C; Steinhelfer L; Chantadisai M; Kroenke M; Koehler D; Pose R; Bannas P; Knipper S; Eiber M; Maurer T
J Nucl Med; 2023 Jul; 64(7):1036-1042. PubMed ID: 37230531
[TBL] [Abstract][Full Text] [Related]
38. A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients.
Wit EMK; KleinJan GH; Berrens AC; van Vliet R; van Leeuwen PJ; Buckle T; Donswijk ML; Bekers EM; van Leeuwen FWB; van der Poel HG
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2861-2871. PubMed ID: 37036490
[TBL] [Abstract][Full Text] [Related]
39. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
Duncan I; Ingold N; Martinez-Marroquin E; Paterson C
Prostate; 2023 Jul; 83(10):970-979. PubMed ID: 37051636
[TBL] [Abstract][Full Text] [Related]
40. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
